ReviewCell host & microbe2020
ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics.
Review in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Planning for the future of the American Society for Microbiology's Health Unit by the Council on Microbial Sciences.mSphere · 2026Review
- Trends of laboratory nonhuman primate licensing in China between 2020 and 2024: A national database analysis.PloS one · 2026Article
- Conformational bias in SARS-CoV-2 Spike CD4+ T-cell epitope dominance.Frontiers in immunology · 2026Article
- Quarantine-associated viral pathogens in non-human primates: pathobiology, diagnostic surveillance, control strategies, and one health implications.Frontiers in veterinary science · 2026Review
- When less is statistically Equivalent: Lobe-Specific optimization of histopathological assessment in SARS-CoV-2 pneumonia.Computers in biology and medicine · 2025Article
- Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.Zoological research · 2024Review
- Comparative transcriptome analysis between rhesus macaques (Zoological research · 2024Article
- Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.Journal of clinical and translational science · 2024Review
- Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.Nature communications · 2023Article
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023Review
- Novel Strategies for the Treatment of COVID-19.Drugs in R&D · 2022Article
- Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19.Viruses · 2022Article
- Article
- Predicting global diet-disease relationships at the atomic level: a COVID-19 case study.Current opinion in food science · 2022Review
- Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).Expert opinion on pharmacotherapy · 2022Article
- Organoid and microfluidics-based platforms for drug screening in COVID-19.Drug discovery today · 2022Review
- Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques.PLoS pathogens · 2022Article
- Nonhuman Primates in Translational Research.Annual review of animal biosciences · 2022Review
- UsingExpert opinion on drug discovery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources. Reviewing SARS-CoV-2 animal model data facilitates standardization and harmonization and informs knowledge gaps and prioritization of limited resources. To date, mouse, hamster, ferret, guinea pig, and non-human primates have been investigated. Several species are permissive for SARS-CoV-2 replication, often exhibiting mild disease with resolution, reflecting most human COVID-19 cases. More severe disease develops in a few models, some associated with advanced age, a risk factor for human disease. This review provides a snapshot that recommends the suitability of models for testing vaccines and therapeutics, which may evolve as our understanding of COVID-19 disease biology improves. COVID-19 is a complex disease, and individual models recapitulate certain aspects of disease; therefore, the coordination and assessment of animal models is imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.